Figure 3From: Targeting of CD34+CD38-cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute Myeloid Leukaemia γH2AX in treated cells. Cells were treated with 10 ng/ml GO, 5 μM tipifarnib or the combination for the indicated times. FACs data are expressed as γH2AX test – isotype control fluorescence intensity compared to untreated cells. (a,b) Summary charts for TF-1a and U937 cells respectively cells after 48 hours’ treatment (c) Illustration of immunofluorescence and FACs plots showing increases in focal (immunofluorescence) and total (flow cytometry) γH2AX following 24 hours of treatment in U937 cells. (d) Summary charts of flow cytometric values for primary AML: bulk (n = 14); CD34+CD38- (n = 9); CD34+CD38+ (n = 8). Median values are shown by a solid bar. * represents a P value compared with untreated cells of <0.05 and ** represents P < 0.01. (e) Line graph showing γH2AX induction in CD34+CD38- cells compared to CD34+CD38+ cells in each of 8 samplesBack to article page